Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Just a heads up.

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Mar 03, 2021 2:49pm

71 Views

Post# 32706942

RE:Just a heads up.

Definitely a wait and see situation.

The other unknown here ... when will they book the $5.4 Million US ?
It's likely they have the option of making the entry in December 2020 or January 2021. Logically they may want to get this behind them & book it earlier rather than later.

Cipher has net earnings of $4.6 million to September 30, 2020. Only $2.0 M (of the $4.6 M) was earned in the 2nd & 3rd quarters combined.
They would need Net Earnings of least $2.2 M in 4th quarter to prevent showing a loss for 2020. What might that do for the share price?

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle